Gastroesophageal reflux disease maintenance therapy

Condra LJ, Morreale AP, Stolley SN, Marcus D. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Manag Care 1999 5(5) 631-8. 

Pashankar D, Blair GK, Israel DM. Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. J Pediatr Gastroenterol Nutr 2001 32(2) 145-9. 

Famotidine (40 mg once a day at bedtime) is indicated for the short-term (4 weeks) treatment of active duodenal ulcer as maintenance therapy for duodenal ulcer at reduced dosage after healing has taken place for shortterm treatment of gastroesophageal reflux disease and in the treatment of hypersecretory conditions such as Zollinger-Ellison syndrome or multiple endocrine adenoma. Famotidine, which is a competitive inhibitor of H2 receptors, inhibits gastric secretion. It is absorbed incompletely (40 to 50%), metabolized partly to an S-oxide metabolite, and partly is excreted unchanged in the urine (see also Table 10 and Figure 23). 

---